2023
Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke
Sperber P, Gebert P, Broersen L, Kufner A, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke. Brain Behavior & Immunity - Health 2023, 34: 100705. PMID: 38033615, PMCID: PMC10684375, DOI: 10.1016/j.bbih.2023.100705.Peer-Reviewed Original ResearchNMDAR1-ABDepressive symptomsHigh titersIschemic strokeProspective cohortEpidemiological Studies Depression ScaleSevere neuropsychiatric symptomsSevere depressive symptomsAutoimmune encephalitisSeronegative patientsAntibody seropositivityIncident strokeSeropositive patientsNeuropsychiatric symptomsSymptoms yearsPatientsLow titersSymptomsTitersCell-based assaysSeropositivityCohortStrokeCESEncephalitis
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies